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KEYWORDS	
	 A	 series	 of	 new	 curcumin	 analogues	 were	 obtained	 by	 Claisen‐Schmidt	 condensation	 of
substituted	benzaldehydes	with	cyclohexanone	derivatives	using	the	ratio	of	1:2	of	ketone	to
aldehyde	 in	 dilute	 ethanolic	 solution	 under	 base	 catalyzed	 (NaOH)	 conditions	 at	 room
temperature	in	good	yields.	The	structures	of	the	synthesized	compounds	were	confirmed	by
data	of	IR,	1H	NMR,	and	13C	NMR	spectra.	
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1.	Introduction	
	
Curcumin,	 1,7‐bis‐(4‐hydroxy‐3‐methoxyphenyl)‐1,6‐
heptadiene‐3,5‐dione,	(Figure	1),	is	a	yellow	compound	isolated	
from	the	rhizome	of	the	herb	curcuma	longa	L.,	which	has	been	
used	 for	 centuries	 as	 a	 dietary	pigment,	 spice,	 and	 traditional	
medicine	in	India	and	China	[1,2].	This	naturally	occurring	and	
synthetic	 compound	 is	 regarded	 as	 a	 promising	drug	 and	has	
received	 considerable	 attention	 due	 to	 its	 antioxidant,	
anticancer,	 anti‐inflammatory,	 anti‐HIV	 and	 antimalarial	
properties	 [3‐7].	 Curcumin	 has	 a	 surprisingly	 wide	 range	 of	
chemo‐therapeutic	activities	and	is	under	investigation	for	the	
treatment	 of	 various	 human	 cancers.	 However,	 the	 clinical	
application	 of	 curcumin	 has	 been	 significantly	 limited	 by	 its	
instability	 and	 poor	 metabolic	 property	 [8‐10].	 Various	
curcumin	 analogues	 have	 been	 synthesized	 to	 overcome	 the	
poor	 metabolic	 property.	 These	 compounds	 have	 been	
attracting	much	more	attention,	not	only	due	to	their	intriguing	
biological	activities	such	as	cyto‐toxicity	[11],	antimycotic	[12],	
antitumor	 [13,14],	 antibacterial	 [15,16],	 anti‐inflammatory	
[17],	and	antileishmaniatic	activities	[18],	but	also	as	important	
precursors	for	the	synthesis	of	heterocyclic	compounds	such	as	
pyrazolines.	 Generally,	 these	 compounds	 are	 prepared	 by	
Claisen‐Schmidt	 condensation	 from	 aromatic	 aldehydes	 and	
ketons	[19].	
In	 the	 present	 work,	 we	 synthesized	 a	 series	 of	 new	
curcumin	 analogues	 3a	 and	 6a‐c	 (Scheme	 1)	 by	 Claisen‐
Schmidt	 condensation	 from	 the	 reaction	 of	 benzaldehydes	 2	
and	5	with	cyclohexanone	derivatives	1	 and	4	 using	NaOH	as	
catalyst.	 Structures	 of	 the	 synthesized	 compounds	 were	
determined	 by	 IR	 and	 their	 spectroscopic	 analyses.	 These	
compounds	 are	 using	 as	 precursors	 to	 prepare	 a	 series	 of	
pyrazoline	 derivatives.	 This	 study	 and	 bioactivities	 of	 all	
synthesis	 compounds	 [20,21]	 will	 be	 the	 subject	 of	 future	
publication.		
	
2.	Experimental	
	
2.1.	Instrumentation	
	
Melting	 points	 were	 determined	 with	 a	
(Bransted/‐Electrothermal)	apparatus	and	are	uncorrected.	 IR	
spectra	 were	 recorded	 in	 KBr	 pellets	 on	 (a	 Perkin‐Elmer	
FT‐IR‐01	and	a	Shimadzu	FT‐	 IR‐	8400S)	spectrophotometers.	
Nuclear	 magnetic	 resonance	 (NMR)	 spectra	 were	 recorded	
using	Bruker	Advance	DRX	400	spectrometer	(400.13	MHz	for	
1H	NMR	and	100.62	MHz	for	13C	NMR)	and	Bruker	Advance	250	
spectrometer	(250.13	MHz	for	1H	NMR	and	62.89	MHz	for	13C	
NMR).	 Chemical	 shift	 values	 are	 reported	 in	 ppm	 relative	 to	
TMS	as	internal	reference	in	CDCl3.	
	
2.2.	Synthesis	
	
A	mixture	 of	 the	 aromatic	 aldehyde	 (20	mmol,	 2	 eq.)	 and	
the	 appropriate	 cyclohexanone	 derivative	 (10	 mmol,	 1	 eq.)	
were	dissolved	 in	15	mL	of	ethanol	 in	a	 simple	necked	round	
bottomed	 flask	 and	 stirred	 for	 several	 minutes	 at	 0	 °C	 (ice	
bath).	 Into	 this	 solution,	 10	 mL	 of	 a	 40	 %	 NaOH	 solution	 in	
water	 was	 then	 added	 drop	 wise	 over	 several	 minutes.	 The	
mixture	 is	 then	 allowed	 to	 stir	 at	 room	 temperature	 for	
approximately	 4	h.	 The	 solid	was	 separated	 and	washed	with	
cold	 water	 and	 dried.	 The	 product,	 so‐obtained,	 was	
crystallized	 from	ethanol	 to	obtain	pure	3a	 and	6a‐c	(Scheme	
1).	
2‐(2‐Fluorobenzylidene)‐5‐methylcyclohexanone	(3a):	Color:	
Yellow	 crystals.	 Yield:	 86%.	 M.p.:	 77‐78	 °C.	 IR	 (KBr,	 ν,	 cm‐1):	
2935	(C‐H),	1678	(C=O),	1610	(C=C).		
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Figure	1. The	keto‐enol tautomerization	of	curcumin.
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Scheme	1
	
	
1H	NMR	 (250.13	MHz,	 CDCl3,	 δ,	 ppm):	1.05	 (d,	 3H,	 J	 =	 5.7	Hz,	
CH3),	1.33‐1.37	(m,	1H,	C‐H),	1.86‐1.93	(m,	1H,	C‐H),	2.07‐2.17	
(m,	 2H,	 C‐H),	 2.55‐2.70	 (m,	 2H,	 C‐H),	 2.86‐2.92	 (m,	 1H,	 C‐H	 ),	
7.05‐7.30	(m,	4H,	Ar‐H),	7.46	(s,	1H,	CH=C).		
2,6‐Bis(4‐fluorobenzylidene)‐4‐methylcyclohexanone	 (6a):	
Color:	Yellow	powder.	Yield:	96%.	M.p.:	124‐125	°C.	IR	(KBr,	ν,	
cm‐1):	 2947	 (C‐H),	 1663	 (C=O),	 1595	 (C=C).	 1H	 NMR	 (400.13	
MHz,	CDCl3,	δ,	ppm):	1.09	(d,	3H,	J	=	8.0	Hz,	CH3),	1.87‐1.89	(m,	
1H,	C‐H),	2.45‐2.51	(m,	2H,	CH2),	2.99‐3.04	(m,	2H,	CH2),	7.08‐
7.12	 (m,	 4H,	 Ar‐H),	 7.43‐7.46	 (m,	 4H,	 Ar‐H),	 7.75	 (s,	 2H,	 2	
CH=C).	 13C	NMR	(100.6	MHz,	CDCl3,	δ,	ppm	):	21.6	 (CH3),	29.3	
(CH),	36.4	(2	CH2),	115.5	(d,	J	=	21.1	Hz,	4	CH	of	Ar‐H	),	132.0	(d,	
J	=	3.0	Hz,	2	Ar‐C),	132.3	(d,	J	=	8.0	Hz,	4	CH	of	Ar‐H),	134.9	(d,	J	
=	2.0	Hz,	2	CH),	136.1	(	2	C=C),	162.6	(d,	J	=	249.5	Hz,	2	Ar‐C	),	
189.8	(C=O).	
4‐Ethyl‐2,6‐bis(4‐fluorobenzylidene)cyclohexanone	 (6b):	
Color:	Yellow	crystals.	Yield:	95%.	M.p.:	118‐119	°C.	IR	(KBr,	ν,	
cm‐1):	2952	(C‐H),	1600	(C=O),	1508	(C=C).	1H	NMR	(250	MHz,	
CD2Cl2,	δ,	ppm	):	0.88	(t,	3H,	J	=	7.5	Hz,	CH3),	1.42	(q,	2H,	J	=	7.5	
Hz,	CH2),	1.65	(m,	1H,	C‐H),	2.45‐2.56	(m,	2H,	CH),	3.03‐3.10	(m,	
2H,	CH),	7.09‐7.16	(m,	4H,	Ar‐H),	7.45‐7.51	(m,	4H,	Ar‐H),	7.71	
(s,	 2H,	 2	 CH=C).	 13C	 NMR	 (100.6	 MHz,	 CDCl3	 ,	 δ,	 ppm):	 11.3	
(CH3),	28.6	(CH2),	34.0	(2	CH2),	35.7	(CH),	115.5	(d,	J	=	21.1	Hz,	
4	CH	of	Ar‐H	),	132.3	(d,	J	=	9.0	Hz,	4	CH	of	Ar‐H	),	132.4	(2	CH),	
135.3	(d,	J	=	1.0	Hz,	2	Ar‐C),	135.6	(2	C=C),	162.7	(d,	J	=	249.5	
Hz,	2	Ar‐C),	189.6	(C=O).		
2,6‐Bis(2,4‐dimethylbenzylidene)‐4‐methylcyclohexanone	
(6c).	 Color:	 Yellow	 crystals.	 Yield:	 91%.	 M.p.:	 178‐179	 °C.	 IR	
(KBr,	 ν,	 cm‐1):	 2949	 (C‐H),	 1662	 (C=O),	 1599	 (C=C).	 1H	 NMR	
(400.13	MHz,	CDCl3,	δ,	ppm):	0.98	(d,	3H,	J	=	4.0	Hz,	CH3),	1.80‐
1.82	(m,	1H,	CH),	2.33	(s,	6H,	2	CH3),	2.37	(s,	6H,	2	CH3)	2.37‐
2.41	(m,	2H,	CH),	2.87‐2.92	(m,	2H,	CH),	7.02–7.07	(m,	4H,	Ar‐
H),	 7.16–7.18	 (m,	 2H,	 Ar‐H),	 7.89	 (s,	 2H,	 2	 CH=C).	 13C	 NMR	
(100.6	 MHz,	 CDCl3,	 δ,	 ppm):	 20.0	 (2	 CH3),	 21.3	 (2	 CH3),	 21.4	
(CH3),	29.9	(CH),	36.6	(2	CH2),	126.1	(2	CH	of	Ar‐H),	129.1	(2	CH	
of	Ar‐H),	131.0	 (2	CH	of	Ar‐H),	132.2	 (2	Ar‐C),	135.4	 (2	Ar‐C),	
136.1	(2	Ar‐C),	138.1	(2	C=C),	138.4	(2	CH),	190.2	(C=O).	
	
3.	Results	and	discussion	
	
With	 a	 view	 to	 synthesize	 compound	 3b,	 3‐
methylcyclohexanone,	 1,	 was	 allowed	 to	 react	 with	 2‐fluoro	
benzaldehyde,	 2,	 in	 ethanol,	 compound	 3a	 were	 obtained	
rather	than	the	compound	3b.	Curcumin	analogues,	6a‐c,	were	
obtained	by	condensation	of	cyclohexanone	derivatives,	4,	with	
substituted	benzaldehydes	5	in	good	yields.		
Compounds	 3a	 and	 6a‐c	 were	 four	 new	 Curcumin	
analogues	characterized	by	melting	points,	IR	and	1H	NMR,	13C	
NMR	 spectra.	 Their	 spectra	 IR	 showed	 a	 strong	 band	 for	 the	
conjugated	 carbonyl	 at	 (1678‐1600	 cm‐1)	 (1609‐1585	 cm‐1	
[22])	 and	 a	 band	 at	 (1610‐1508	 cm‐1)	 for	 C=C	 group	 (1515‐
1446	cm‐1	[22]).	In	the	1H	NMR	spectra	of	new	α,β‐unsaturated	
ketones,	 the	olefinic	proton	gave	a	 singlet	 signal	at	 (7.89‐7.46	
ppm)	(7.82‐7.16	ppm,	[22]).	13C	NMR	chemical	shifts	of	the	C=O	
group	have	 been	 assigned	 at	 (190.2‐189.6	ppm)	 (191.3‐188.5	
ppm	[22]).	
	
	
148	 Ziani	et	al.	/	European	Journal	of	Chemistry	4	(2)	(2013)	146‐148	
	
4.	Conclusion		
	
Due	 to	 the	 importance	 of	 curcumin	 analogues,	 their	wide	
range	 of	 biological	 activities,	 and	 applications	 in	 synthesis	 of	
pyrazolines,	 we	 have	 synthesized	 a	 series	 of	 new	 curcumin	
analogues	 3a,	 6a‐c	 by	 Claisen‐Schmidt	 condensation.	 These	
compounds	 can	 be	 as	 precursors	 to	 prepare	 a	 series	 of	
pyrazoline	 derivatives.	 The	 bioactivities	 of	 all	 synthesized	
compounds	 will	 be	 the	 subject	 of	 future	 publication.	 The	
synthesized	curcumin	analogues	are	very	stable	compounds,	a	
property	 which	 may	 render	 them	 as	 important	 synthetic	
precursors	in	organic	chemistry	and	useful	substances	in	drug	
research	to	overcome	the	poor	metabolic	property	of	curcumin.		
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